UnitedHealth Group Incorporated (UNH)
UnitedHealth Group (UNH) is trading at $405.80, exhibiting strong upward momentum. The company operates within the Healthcare sector, specifically in Healthcare Plans, competing with peers like CVS Health (CVS) and Elevance Health (ELV). Recent insider activity shows a significant net buying trend, with insiders purchasing $32.1M versus selling $473.3K, signaling confidence from management. This positive insider sentiment, coupled with favorable technicals, underpins the current bullish outlook for UNH.
Fundamentally, UNH's P/E ratio stands at 30.44, which is above the sector average, suggesting a premium valuation. However, the consistent revenue growth of 2% and strong EPS of $13.26 indicate underlying business strength. The company's market capitalization of $368.52B reflects its significant scale within the healthcare industry. While the valuation is rich, the combination of insider conviction and technical strength suggests potential for continued appreciation.
Price Analysis
Market Metrics
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
UNH Analysis
UnitedHealth Group's technical profile is predominantly bullish. The stock is trading above its 50-day SMA ($378.62) and 200-day SMA ($334.99), indicating a strong uptrend. The 20-day EMA ($398.87) also shows the price is trading above this shorter-term average, reinforcing positive momentum. The RSI is at 69.56, signaling bullish momentum without being excessively overbought, suggesting room for further upward movement. The MACD at 8.90 further supports this positive trend.
Key support levels are observed around the moving averages, particularly the 50-day SMA. Resistance levels are less defined on the provided data but are likely to be tested as the price continues its ascent. The Stochastic indicator at 61.09 and CCI at 20.56 also point towards a healthy upward trend. Overall, the technicals suggest that UNH is in a strong bullish phase, with current levels acting as support for potential further gains.
- Monitor upcoming earnings reports closely for any signs of accelerating revenue growth or margin expansion that could justify UNH's premium valuation.
- Given the strong bullish technicals, consider using moving averages like the 50-day SMA ($378.62) as potential support levels for entry or stop-loss points.
- The significant insider buying suggests management's conviction; however, always balance this with fundamental valuation and sector-specific risks.
Insiders have purchased $32.1M in stock versus only $473.3K in sales, indicating significant confidence in the company's future prospects.
Source: Insider TransactionsThe stock is trading above key moving averages (50-day SMA, 200-day SMA, 20-day EMA) with a bullish RSI, suggesting continued upward price action.
Source: Technical AnalysisThe median analyst target price of $435.00 suggests an approximate 7.20% upside from the current trading price.
Source: Wall Street SummaryUNH's P/E ratio of 30.44 is notably higher than the sector average of 22.50, posing a risk if growth falters.
Source: Fundamental AnalysisThe reported 2% revenue growth is stable but lags the sector average, indicating potential limitations on future expansion pace.
Source: Company FinancialsThe outlook for UnitedHealth Group (UNH) remains positive, driven by strong insider confidence and robust technical momentum. We project a base case scenario where UNH continues its upward trend, potentially testing higher price levels in the next 6-12 months, supported by its dominant market position and consistent earnings. A target price range of $420-$435 seems achievable, reflecting a slight premium over the current price and aligning with analyst targets.
Upside catalysts could include better-than-expected earnings reports, strategic acquisitions, or favorable regulatory developments. Conversely, downside risks include increased regulatory pressure, a broader market downturn impacting healthcare stocks, or failure to meet elevated growth expectations, which could lead to a valuation multiple contraction. The company's ability to navigate these risks while maintaining its operational strength will be key to its future performance.
Key Statistics
| Market Cap | 368.52B |
| P/E Ratio | 30.44 |
| EPS (TTM) | 13.26 |
| Dividend Yield | 2.21% |
| 52 Week High | 415.98 |
| 52 Week Low | 234.60 |
UnitedHealth Group's valuation metrics, including a P/E ratio of 30.44, place it at a premium compared to the broader healthcare sector average of 22.50. This suggests investors are willing to pay more for UNH's earnings, likely due to its market leadership and consistent performance. The EPS of $13.26 supports the current stock price, but the premium valuation warrants scrutiny, especially considering the modest 2% revenue growth. Investors should monitor if future earnings can justify this higher multiple.
The company's balance sheet strength and profitability are key drivers. While specific margin data isn't provided, the EPS figure implies solid profitability. The dividend yield of 2.21% offers a modest income stream. The market cap of $368.52B underscores its position as a dominant player. The fundamental picture is one of a high-quality company trading at a premium, where growth and stability are priced in, making future performance critical for sustaining this valuation.
Earnings & Growth Analysis
UnitedHealth Group's reported EPS of $13.26 indicates strong profitability. While specific recent earnings beats or misses are not detailed in the provided data, the EPS figure itself suggests robust operational performance. The company's consistent ability to generate earnings is a key factor supporting its premium valuation and market position within the Healthcare Plans industry.
The 2% revenue growth, while not explosive, is steady for a company of UNH's scale. This indicates a stable, mature business model that continues to expand its top line. Investors will be looking for continued earnings power and potential acceleration in revenue growth to justify the current market valuation and support future stock performance.
Key Risks
The primary risk for UnitedHealth Group is its premium valuation. A P/E ratio of 30.44, significantly above the sector average, leaves little room for error and could lead to a sharp correction if growth expectations are not met. Additionally, regulatory scrutiny within the healthcare sector remains a persistent overhang, with potential policy changes impacting profitability and business operations.
Competitive pressures from other large healthcare providers like CVS Health (CVS) and Elevance Health (ELV) also pose a risk. While UNH has a strong market position, intensified competition could pressure margins and market share over the long term. The modest 2% revenue growth also presents a risk if it fails to accelerate, potentially disappointing investors seeking higher growth profiles.
Technical Indicators
| RSI (14) | 69.56 |
| MACD | 8.90 |
| SMA 50 | 378.62 |
| SMA 200 | 335.00 |
Actionable Trade Plans
Specific entry, exit, and risk management levels
Entry Strategies (click to switch)
Risk Management
Profit Targets (Based on Conservative Entry)
Growth of $10,000
Compare with Another Ticker
Monte Carlo Projection (10yr)
People Also Watch
Insider Trading Analysis
Source: SEC Form 4| Date | Insider | Type | Shares | Value |
|---|